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ABSTRACT The rat protein tyrosine phosphatase h, rPTPh, is a class I ‘‘classical’’ transmembrane RPTP, with an intracellular
portion composed of a unique catalytic region. The rPTPh and the human homolog DEP-1 are downregulated in rat and human
neoplastic cells, respectively. However, the malignant phenotype is reverted after exogenous reconstitution of rPTPh, suggesting
that its function restoration could be an important tool for gene therapy of human cancers. Using small-angle x-ray scattering
(SAXS) and biophysical techniques, we characterized the intracellular catalytic domain of rat protein tyrosine phosphatase h
(rPTPhCD) in solution. The protein forms dimers in solution as conﬁrmed by SAXS data analysis. The SAXS data also indicated
that rPTPhCD dimers are elongated and have an average radius of gyration of 2.65 nm and a Dmax of 8.5 nm. To further study
the rPTPhCD conformation in solution, we built rPTPhCD homology models using as scaffolds the crystallographic structures
of RPTPa-D1 and RPTPm-D1 dimers. These models were, then, superimposed onto ab initio low-resolution SAXS structures.
The structural comparisons and sequence alignment analysis of the putative dimerization interfaces provide support to the notion
that the rPTPhCD dimer architecture is more closely related to the crystal structure of autoinhibitory RPTPa-D1 dimer than to
the dimeric arrangement exempliﬁed by RPTPm-D1. Finally, the characterization of rPTPhCD by ﬂuorescence anisotropy
measurements demonstrates that the dimer dissociation is concentration dependent with a dissociation constant of 21.66 2.0 mM.
INTRODUCTION
Protein tyrosine phosphorylation is a reversible posttransla-
tional modiﬁcation involved in regulation of physiological
processes as well as human health and disease. The antag-
onistic activities of protein tyrosine kinases (PTKs) and pro-
tein tyrosine phosphatases (PTPs) dictate the intracellular
levels of protein tyrosine phosphorylation, one of the most
important eukaryotic cell signaling mechanisms (1–4). The
increasing number and diversity of protein tyrosine kinases
and phosphatases has been directly related to the increase in
eukaryotic complexity. In recent years it became evident that,
like PTKs, the PTPs play important roles in many cellular
processes such as embryogenesis, organ development, tissue
homeostasis, the immune system, fertilization, cell migration,
and proliferation (5–7). The protein tyrosine phosphatases
belong to a large group of enzymes that are subdivided into
four main families based on the amino acid sequence of their
catalytic domains and substrate speciﬁcity (8). The class I
cysteine-based PTPs constitute by far the largest group and
contain the 38 strictly tyrosine-speciﬁc PTPs. The ‘‘classical
PTPs’’ can be further divided into transmembrane, receptor-
like enzymes (RPTPs), and the intracellular, nonreceptor
PTPs (NRPTPs), all sharing an intracellular catalytic domain
of ;240 residues. Its active site bears a signature motif
(PIVVHCSAGvGRTG) where the catalytically essential cys-
teine and arginine are separated by ﬁve residues (9,10). The
crystal structures of all known RPTP catalytic domains re-
vealed a common architecture comprising: a globular fold that
consists of an eight-stranded twisted b-sheet ﬂanked by four
a-helices on one side and another one on the opposite side; the
PTP signature motif located at the bottom of the catalytic site
cleft; and four loops, three of which provide residues needed
for catalysis and substrate speciﬁcity (11–13).
The rat protein tyrosine phosphatase h, rPTPh, is a class I
‘‘classical’’ transmembrane RPTP, and like its human coun-
terpart (also known as DEP-1, PTPRJ, RPTPh, and CD148)
it is a ubiquitous gene. In fact, rPTPh is expressed in all
studied tissues, including brain, liver, spleen, thyroid, and en-
dothelial cells. The receptor-like rPTPh consists of an ex-
tended extracellular region containing eight ﬁbronectin type
III motifs, a short transmembrane domain, and an intracel-
lular portion composed of a unique catalytic region (14).
Soon after its discovery, it was reported that rPTPh expression
is regulated by the two main thyroid regulatory pathways,
suggesting it involvement in both growth and differentiation
of thyroid cells (15). Further observations demonstrated that
rPTPh and the human homolog DEP-1 are downregulated in
rat and human neoplastic cells, respectively. However, the
malignant phenotype can be reverted after exogenous recon-
stitution of rPTPh through increasing levels of cell cycle in-
hibitor p27Kip1 and dephosphorylation of PLCg1, a substrate
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of DEP-1 (16–19). It was also demonstrated that the PTPh
protein is capable of binding to c-Src in living cells. The de-
phosphorylation of the negative regulatory tyrosine (Tyr-529
of the c-Src family protein tyrosine kinases) increases c-Src
tyrosine kinase activity in malignant rat thyroid cells stably
transfected with rPTPh (20). Besides, the implication of
PTPh as a possible candidate for the mouse colon-cancer
susceptibility locus, Scc1, came to reinforce the idea that res-
toration of rPTPh function could be a useful tool for gene
therapy of human cancers (21–23).
Although the process of RPTP activity regulation remains
elusive, one of the proposed structural mechanisms involves
formation of an autoinhibitory dimeric quaternary structure.
Structural evidence supporting such a mechanism came from
the crystal structure of RPTPa-D1 (24). RPTPa-D1 was
crystallized as a dimer with two active sites facing each other
and the amino-terminal helix-turn-helix wedge-like segment
of each monomer blocking the opposing active site (24). In
addition, functional inhibition of RPTPs was observed in
ligand-induced dimerization of EGFR/CD45, a chimeric pro-
tein containing the extracellular domain of the epidermal
growth factor receptor (EGFR), and the intracellular domain
of the RPTP, CD45 (25), as well as in the full-length mutants
of RPTPa assembled as stable disulphide-bonded homodimers
(26,27). By contrast, the crystal structures of both RPTPm-D1
that shares 46% sequence identity with RPTPa-D1 reveal
completely different dimer formation. The RPTPm-D1 dimer
has neither the catalytic sites nor the amino-terminal helix-
turn-helix segment participating in protein-protein interac-
tions (28). Taking these results together one can conclude
that although dimerization seems likely to be of physiolog-
ical relevance in blocking the biological activity of RPTPa
and CD45, it might not be a general mechanism of RPTP in-
hibition.
In this study, we conducted a structural and biophysical
characterization of rPTPh catalytic domain with use of small
angle x-ray scattering (SAXS), homology modeling, amino
acid sequence alignment, and ﬂuorescence anisotropy tech-
niques, aiming to determine the protein molecular shape and
its oligomeric state in solution and to shed more light onto
the putative autoinhibitory mechanism that might control
rPTPh enzymatic activity.
EXPERIMENTAL PROCEDURES
Protein expression and puriﬁcation
The catalytic domain of rPTPh has been subcloned, expressed, and puriﬁed
as described in Santos et al. (29). Brieﬂy, the cloned construct contained the
open reading frame of the intracellular region of rPTPh (W875-A1216)
fused at its N-terminus with the 34 additional amino acid residues
(MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGS) derived from
pET-28a(1) vector that included the cluster of six histidine residues for
protein puriﬁcation by metal afﬁnity chromatography. BL21 (DE3) cells
harboring the plasmid containing rPTPhCD insert were grown at 30C in
23 YT plus 50 mg/ml kanamycin with shaking until the absorbance at 600
nm reached 0.6–0.8. At this point, 0.5 mM isopropyl-b-D-thiogalactopyr-
anoside was added to induce His6-rPTPhCD expression and cells were
incubated at 30C for 4 h. The induced bacteria were harvested by cen-
trifugation at 60003 g in a Sorvall RC-5C Plus centrifuge at 4C for 20 min.
Bacterial pellets were ressuspended in lysis buffer (50 mM sodium
phosphate buffer, pH 7.8; 100 mM NaCl; 10% glycerol; 10 mM imidazol;
2 mM b-mercaptoethanol) containing 1 mM phenylmethanesulfonyl ﬂuo-
ride and 0.5 mg/ml of lysozyme (Sigma, St. Louis, MO). The suspension
was incubated on ice for 30 min to lyse cells. The lysate was further dis-
rupted by sonication to reduce viscosity. Centrifugation was done at 14,000
3 g for 1 h to obtain the clear crude protein preparation. Talon Superﬂow
resin (Clontech, Palo Alto, CA), preequilibrated with equilibration buffer
(50 mM sodium phosphate buffer, pH 7.8; 300 mM NaCl; 10% glycerol;
10 mM imidazol; 2 mM b-mercaptoethanol) was mixed with the clear lysate
and left rotating at 4C for 1 h. The mixture of resin and supernatant was
mounted into a c16/10 glass column (Amersham Biosciences, Uppsala,
Sweden) and connected to a high-performance liquid chromatography A¨KTA
puriﬁer (Amersham Biosciences). The tightly bound proteins were eluted
with buffer containing 50 mM sodium phosphate buffer, pH 7.8; 50 mM
NaCl; 10% glycerol; 300 mM imidazol; 2 mM b-mercaptoethanol. The
His6-rPTPhCD was further puriﬁed by size exclusion chromatography on a
Superdex 200 HL 26/60 column (Amersham Biosciences) using as eluent
Hepes buffer (20 mM Hepes, pH 7.8; 200 mM NaCl; 5% glycerol; 1 mM
dithiothreitol). All puriﬁcation procedures were carried out at 4C. Soluble
His6-rPTPhCD (molecular weight of 43,000) was concentrated to 1 mg/ml
and incubated with 0.5 units/ml bovine thrombin protease for 18 h at 18C
followed by dialysis against Hepes buffer. The thrombin cleaved rPTPhCD
(molecular weight of 41,000) was, then, frozen in liquid nitrogen and stored
at 80C (29).
Protein concentration measurements
Protein concentration was determined by the method of Bradford (30) with
bovine serum albumin (Sigma) as reference standard, using the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA).
Small-angle x-ray scattering measurements and
scattering data analysis
Small-angle x-ray scattering experiments were carried out at the SAS beam
line on the Brazilian National Synchrotron Light Laboratory (Campinas, Sao
Paulo, Brazil), using a one-dimensional position-sensitive detector (31).
SAXS data were collected at a wavelength 0.148 nm for sample-detector
distance of 1046.3 mm to give a q-range from 0.28 nm1 to 3.40 nm1 (q ¼
4*sinu/l, where 2u is the scattering angle). rPTPhCD concentrations
between 3 and 13 mg/ml were prepared in Hepes containing 200 mM NaCl
and maintained at a constant temperature of 4C during the measurements.
The scattering curves of the protein solutions and buffers were collected in
several successive frames of 100 s each to avoid radiation-induced protein
damage. The data reduction included normalization of the one-dimension
scattered data to the intensity of the transmitted incident beam; correction for
the detector response; and subtraction of the scattering of the buffers. After
scaling all scattered curves for protein concentration, the composed scat-
tering curves were constructed by merging the low angle data (,0.85 nm1)
obtained at 3 mg/ml with the high angle data, measured at 13 mg/ml, which
were, then, used in ab initio model reconstruction.
Guinier analysis (32) was applied to determine the radii of gyration (Rg)
of rPTPhCD in solution. The Rg and the scattered intensity, I(q), were in-
ferred, respectively, from the slope and the intercept of the linear ﬁt of
ln[I(q)] vs. q2 in the q-range q 3 Rg , 1.0. The same parameter was also
obtained from the theoretical ﬁt of the merged curve by the indirect Fourier
transform program GNOM (33), which also evaluated the distance dis-
tribution function, p(r), of rPTPhCD. The maximum dimension, Dmax, was es-
timated from the p(r) function as the distance, r, where p(r) goes down to zero.
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Ab initio molecular shape determination and
DAMAVER program
Ab initio models were calculated using the well-established reconstruction
method DAMMIN, to determine the conformation in solution of rPTPhCD
(34). Using the simulated annealing method, the program searches for the
best dummy atom model (DAM) that ﬁts the experimental data through
minimizing the discrepancy function, f(X), between the calculated and
experimental curves. A looseness penalty ensures the compactness and
connectivity of the solution, Eq. 1, where a . 0 is the positive weight
of the looseness penalty, aP(X).
f ðXÞ ¼ x21aPðXÞ: (1)
The overall shape of the protein was restored from the complete range of
q (0.28 nm1 , q, 3.40 nm1), which allowed a reasonable resolution for
the discrete DAM. In each of 20 independent low-resolution reconstructions
of molecular shape, a sequence of 87 6 3 independent runs was carried out
to obtain the most probable model without imposing any symmetry con-
strains. During this procedure, a constant was subtracted from the exper-
imental data to ensure that the intensity at higher angles decays as q4
following Porod’s law for the homogeneous particles (35). The value of the
constant was derived automatically from the outer part of the curve by linear
ﬁtting in coordinates q4I(0) versus q4 by the program DAMMIN.
DAMAVER was used for automated analysis and averaging of multiple
reconstructions, permitting both to analyze the stability of the reconstruction
convergence and to yield the most probable particle model (36,37).
Homology model building of rPTPhCD
The coordinate sets for the monomeric and dimeric crystallographic struc-
tures of the catalytic domain (D1) of mouse RPTPa and human RPTPmwere
obtained from the Protein Data Bank ((PDB) codes 1YFO and 1RPM, re-
spectively) (24,28). The Rg, Dmax, and scattering curves were calculated
from the dimeric structures by the program CRYSOL (38), taking into ac-
count the inﬂuence of the hydration shell.
Computer models for the three-dimensional (3D) structure of rPTPhCD
were constructed using homology modeling, which requires available 3D
structures as templates. The mouse protein tyrosine phosphatase a has
43.21% identity to the rPTPhCD sequence, and it was selected as the
template for homology model generation with the Modeller program (39).
We produced 100 models, each of which was validated using the programs
Procheck (40,41), Whatcheck (42), and Verify3D (43,44). The best model
was chosen using as criteria the energy function calculated by the Modeller
program, the Ramachandran plot, and absence of structural anomalies. The
best homology model was superimposed with the dimeric crystallographic
structures of RPTPa-D1 andRPTPm-D1 using SUPCOMB (36), which com-
putes and carries out best-matching alignment of the 3D models. The same
program was used for superpositions of high-resolution models with ab initio
low-resolution structures derived from experimental solution-scattering data.
Fluorescence anisotropy measurements
Fluorescence anisotropy experiments were carried on the ISS PC1 spec-
troﬂuorimeter equipped with Glan-Thompson polarizers (ISS, Champaign,
IL). rPTPhCD at a concentration of 0.22 mMwas labeled by incubation with
1 mM ﬂuorescein isothiocyanate ((FITC) Sigma) in Hepes buffer (20 mM
Hepes, pH 7.8; 200 mMNaCl; 5% glycerol; 1 mMDTT), at 4C for 3 h. Free
FITC was separated from labeled rPTPhCD using Hitrap desalting column
(GE Healthscience, Madison, WI) equilibrated with Hepes buffer. Protein
labelingwas conﬁrmed by absorbance spectrophotometry, showing both pro-
tein and ﬂuorescein contributions in the absorption spectra. The labeling
efﬁciency was of ;0.24 mol ﬂuorescein per mol protein, as calculated from
FITC=rPTPhðmol=molÞ ¼ ðA494=e494FITCÞ=½ðA280  A494
 ðe280FITC=e494FITCÞÞ=e280rPTPh; (2)
where A280 and A494 are the absorption at 280 and 494 nm, respectively,
e494FITC ¼ 68,000 M1cm1, and e280FITC ¼ 20,000 M1cm1 are the extinction
coefﬁcient for protein-bound FITC at 280 and 494 nm, respectively (45,46).
e280rPTP ¼ 63,050M1cm1 is the extinction coefﬁcient for rPTPh catalytic do-
main at 280 nm calculated on the basis of its amino acid sequence (residues
W875-A1216 of rPTPh; ‘‘Protein expression and puriﬁcation’’ section)
assuming six tryptophan residues, 20 tyrosine residues, and at most two
cystines (47). The low efﬁciency of labeling, probably due to the pH
and temperature conditions used in the reactions, is advantageous because
it diminishes the chances of self-transfer between ﬂuorophores on the
same protein molecule.
Fluorescein-rPTPhCD at a concentration of 10 nM was titrated with
unlabeled rPTPhCD at 20C in Hepes buffer. Fluorescence anisotropy of the
labeled solution of rPTPhCD was excited at 480 nm and emission measured
through a band-pass ﬁlter with a cutoff of 50% at 515 nm, as previously de-
scribed (48). For each concentration of unlabeled protein, the data point
represents the mean of at least ﬁve measurements after stabilization. The
resulting anisotropy change was used to calculate the dissociation equilib-
rium constant by adjusting Eq. 3 to the experimental data:
fd ¼ ½rPTPhCD=ðKd1 ½rPTPhCDÞ; (3)
where fd is the fraction of protein dimers and Kd is the dissociation constant.
As the association led to a discrete increase in ﬂuorescence intensity
(;40%), we applied correction:
fd ¼ ðAobs  AmÞ=½ðAobs  AmÞ1 ðFd=FmÞðAd  AobsÞ; (4)
where Aobs, Am, and Ad are, respectively, the rPTPhCD-labeled anisotropy
values observed at a given concentration of unlabeled rPTPhCD, for the
monomeric rPTPhCD and dimeric rPTPhCD (49). The corrections per-
formed on changes in ﬂuorescence intensity make use of the total ﬂuores-
cence intensity IT directly provided by the instrument software, according to:
IT ¼ Ik1 2I?; (5)
where Ik and I? are, respectively, the time-independent steady-state values
for ﬂuorescent intensity polarized parallel and perpendicular to that of the
excitation beam. Binding data were analyzed using SigmaPlot 2002
Windows Version 8.0.
RESULTS AND DISCUSSION
Small-angle x-ray scattering measurements
demonstrate that rPTPhCD is capable of
dimer formation
The biological activity of the puriﬁed rPTPhCDwas tested in
vitro by hydrolysis assay. The results demonstrated that
rPTPhCD was active and able to hydrolyze p-nitrophenyl
phosphate (29). To obtain information about the size, mole-
cular shape, and oligomeric state of rPTPhCD in solution, we
submitted the protein to small-angle x-ray scattering analysis.
rPTPhCD x-ray scattering curve is shown in Fig. 1 A. The
Guinier analysis, in the q2-range from 0.08 to 0.24 nm2,
reproducibly gave estimates of 2.59 nm for the radius of
gyration of rPTPhCD. The linearity of the Guinier plot indi-
cated that rPTPhCD preparation was monodisperse and
constituted mainly by unique oligomeric species (Fig. 1 A,
inset).
The pair-distance distribution function p(r) was obtained
by the inverse Fourier transform of the rPTPhCD scattering
data, using the program GNOM (33). Analysis of the p(r)
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function led us to conclude that the protein has an elongated
form with a Dmax of 8.50 6 1.00 nm (Fig. 1 B). The value
of 2.65 6 0.02 nm for Rg calculated from the distance
distribution function is in good agreement with the estimate
derived from the Guinier analysis (Table 1). To compare
rPTPhCD with the existing high-resolution structures, we
also computed the theoretical scattering curves and the pair-
distance distribution function for the crystal structures of
RPTPa-D1 and RPTPm-D1 dimers by using the program
CRYSOL (38) (Fig. 1, A and B). The radii of gyration
observed for RPTPa-D1 and RPTPm-D1 were 2.72 and
2.82 nm, and the Dmax values were 9.95 and 9.50 nm, re-
spectively. Comparison of these simulated SAXS curves
with the experimental data for rPTPhCD revealed discrep-
ancy values for RPTPa-D1 and RPTPm-D1 of 1.47 and 2.22,
respectively, for RPTPa-D1 and RPTPm-D1. SAXS results
reveal that in solution at the concentrations studied the
rPTPhCD appears predominantly as dimers with a molecular
shape similar to that of RPTPa-D1 (Fig. 1, A and B, and
Table 1). The dimeric state of rPTPhCD also was conﬁrmed
by native gel electrophoresis (not shown).
Ab initio molecular shapes of rPTPhCD and its
high-resolution models
The ab initio low-resolution structure of rPTPhCD was
determined from the SAXSdata using the programDAMMIN
(34) without any symmetry constraints (Table 1). An average
of 10 independently generated dummyatommodels produced
by theDAMAVERpackage ﬁttedwell the experimental x-ray
scattering curve (x ¼ 1.06; Table 1). The low-resolution
rPTPhCD dimer has an elongated ‘‘cigar-like’’ shape with
;3:1 ratio between its longest and shortest dimensions
(Fig. 2). Given that the dimeric arrangement is important for
rPTPh function, we attempted to model it using as templates
the homologous RPTPa-D1 and RPTPm-D1 dimer.
The rPTPhCD dimer homology models based on the
RPTPa-D1 and RPTPm-D1 crystal structures templates were
automatically superposed, using the program SUPCOMB
(36), as rigid bodies with the ab initio low-resolution structure
of the protein (Figs. 2 and 3). After automated best-matching
alignment procedure, visual analysis clearly indicates that
RPTPa-style dimer (Fig. 2) ﬁts the rPTPhCD low-resolution
structure better than the RPTPm-D1-based homology model
(Fig. 3). Furthermore, in the case of the RPTPa-D1-type
FIGURE 1 Small angle x-ray scattering curves. (A) Experimental solution
scattering curve of rPTPhCD and results of the ﬁtting procedures. Intensity
curves from rPTPhCD are shown as logarithm (log I) versus the momentum
transfer q scale, with an inset containing the correspondent Guinier plots (log
I vs. q2). The desmeared experimental curve (open squares) denotes the
SAXS data and the error bars indicate the standard uncertainty in the
measurement. The dashed curve corresponds to the best-ﬁt model produced
by DAMMIN (34). The black solid line is the theoretical scattering intensity
from the dimer homology model based on the RPTPa-D1 (PDB code,
1YFO). The gray solid line is the scattering intensity computed from the
dimer homology model based on the RPTPm-D1 crystal structure (PDB
code, 1RPM). (B) Distance distribution function of rPTPhCD. The p(r)
values of rPTPhCD (open squares) computed from the experimental
scattering curves by the indirect Fourier transform program GNOM (33).
The maximum dimension (Dmax) is equal to 8.506 1.00 nm. The black solid
curve corresponds to p(r) derived from dimer homology model based on the
RPTPa-D1 dimer. The p(r) derived from dimer homology model based on
the dimer of RPTPm-D1 is given as a gray solid line. The distance
distribution function for RPTPa-D1 dimer is clearly more similar to the
experimentally derived p(r) for rPTPhCD than the one calculated on the
basis of RPTPm-D1 dimer model.
TABLE 1 Structural parameters
rPTPhCD
Parameter/sample Exp* rPTPa rPTPm DAMy
Dmax (nm) 8.50 6 1.00 9.95 9.5 8.72
Rg (nm) 2.65 6 0.02 2.72 2.82 3.35
Free parameters 8z – – 1926§
Discrepancy x – 1.47 2.22 1.06
Resolution (nm) 1.85{ – – 1.85{
*Exp, calculated from the experimental data.
yDAM, parameters of the dummy atoms models averaged over 10 models.
zNumber of Shannon channels is given Ns ¼ [Dmax(qmax  qmin)]/p.
§Symmetry not imposed.
{Resolution is calculated as 2p/qmax.
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dimer, the normalized spatial discrepancy (NSD) value is
equal to 0.823, whereas for the dimer of RPTPm-D1-type the
NSD value was 0.993. Because we can assume structural
similarity between models with NSD values ,1 (41), these
results provide further support to the idea that in solution
rPTPhCD forms dimers with the molecular shape resembling
the dimer arrangement revealed by the crystallographic
structure of RPTPa-D1.
To gain more data with respect of rPTPhCD dimerization
mode, we compared amino acid sequence composition at the
putative dimer interfaces of the two proposed models with
that of the dimerization interface of RPTPa-D1 and RPTPm-
D1 (Fig. 4). Although the overall sequence identity between
rPTPhCD and these two phosphatases is similar (43.21% for
RPTPa-D1 and 45.16% for RPTPm-D1), the same is not true
for the dimerization regions: 17 out of 30 residues (56.7%)
on the dimerization interface of RPTPa-D1 are conserved in
rPTPhCD, whereas only ﬁve out of 19 residues (26.3%) are
conserved in rPTPhCD at the dimerization interface of
RPTPm-D1 (Fig. 5). This lends further support to the hypo-
thesis that rPTPh dimerization might be similar to the RPTPa
dimer architecture in which the N-terminal helix-turn-helix
segment of the dyad-related monomer sterically blocks the
opposite active site.
Fluorescence anisotropy measurements provide
an equilibrium dissociation constant of the
rPTPhCD dimers
To determine the equilibrium dissociation constant of the
rPTPhCD dimer, we labeled the recombinant protein with
FIGURE 2 Three orthogonal stereoviews of the ab initio low-resolution
rPTPhCD structure superposed with the dimeric homology model of
rPTPhCD based on the crystallographic structure of RPTPa-D1. The ﬁgure
was prepared using PyMOL (DeLano Scientiﬁc, San Carlos, CA; http://
www.pymol.org).
FIGURE 3 Three orthogonal stereoviews of the homology model of the
putative rPTPhCD dimer based on the crystallographic structure of RPTP
m-D1 superposed on the low-resolution ab initio rPTPhCD molecular
envelope. The ﬁgure was prepared using PyMOL (DeLano Scientiﬁc).
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ﬂuorescein isothyocianate (FITC), which reacts with amino
terminus of proteins and the e-amino group of lysines (50).
Fluorescence spectra of both buffer and ﬂuorescein-labeled
rPTPhCD are shown in Fig. 6 A. Puriﬁed ﬂuorescein-labeled
rPTPhCD (FITC-rPTPhCD) at 10 nM shows an anisotropy
value of ;0.085 (Fig. 6 B), which is compatible with a
protein-bound ﬂuorescein value but largely different from
the typical values of free ﬂuorescein anisotropy (of the order
of 0.014). Equilibration of 10 nM FITC-rPTPhCD with
increasing amounts of unlabeled rPTPhCD (from 7.2 nM to
36 mM) led to an increase in ﬂuorescein ﬂuorescence an-
isotropy values, indicating multimerization (Fig. 6 B). Be-
cause we know from SAXS and native gel electrophoresis
studies that at 50 mM rPTPhCD is dimeric, these changes in
anisotropy values as a function of rPTPhCD concentration are
indicative of a monomer-dimer equilibrium. The rPTPhCD
dimer dissociation constant of 21.66 2.0 mMwas calculated
by adjusting Eq. 3 to experimental data. This Kd corresponds
to a Gibbs free-energy value of DG0293K ¼ 6.2 kcal/mol.
On the basis of theoretical evaluations, it is expected that
protein dissociation (from 10 to 90%) would occur within a
protein concentration log span of 2.86 (51,52). Our exper-
imental data demonstrate that rPTPhCD dimers dissociation
presents a signiﬁcantly shortened log span of 1.5. A similar
behavior leading to a reduced span in the dimerization iso-
therms has already been observed for a number of proteins,
such as malate dehydrogenase (53), yeast enolase (51), arc
repressor (54), and O2bZIP (55), to name a few. The
deviations from the expected span in dimerization isotherms
have been attributed to a conformational drift of the protein,
i.e, a change in quaternary interactions affecting the structure
and conformation of each subunit upon dimerization process
(52). This indicates that subunits of the dimeric and mono-
meric species of rPTPhCD are conformationally different.
A number of RPTPs, as well as RPTKs, are known to
function as transmembrane dimers and dimerization could be
a common phenomenon for RPTPs in general (26,27,56).
Although the dimeric interaction seen for soluble rPTPhCD
is ;22 mM, this afﬁnity is expected to be enhanced sub-
stantially for the full-length receptors in the cell membrane.
In fact, both local protein concentrations and monomer-
monomer afﬁnities could be signiﬁcantly higher for the func-
tional rPTPh dimers bound to the membrane of cell. Under
these settings two extracellular domains of PTPh, each
composed of eight ﬁbronectin type 3 motifs, will also con-
tribute to PTPh dimer formation. Membrane anchoring,
which restricts both PTPh translational movement in the di-
rection perpendicular to the membrane surface, and its rota-
tional freedom around the axes within the membrane plane,
will lead to further increase in association afﬁnity of PTPh
dimer. It has been argued that the binding afﬁnities of the
molecules in two-dimensional diffusion case are signiﬁ-
cantly (orders of magnitude) higher than observed in solution
(57,58). Therefore, afﬁnities of dimers association are
FIGURE 4 Sequence alignment for RPTPa-D1,
RPTPm-D1, and PTPhCD. The sequence of PTPhCD
corresponds to the intracellular domain of the protein
studied in current work (residues W875–A1216). The
sequences of RPTPa-D1 and RPTPm-D1 are of the
polypeptide chains structurally deﬁned in PDBs 1YFO
and 1RPM, respectively. The residues at the dimerization
interfaces are marked in gray (RPTPa-D1) and black
(RPTPm-D1). Residues in rPTPhCD amino acid sequence
are gray when they match the correspondent residues of the
RPTPa-D1 dimerization interface; they are black when
identical to residues at the dimerization interface of
RPTPm-D1.
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expected to be substantially enhanced, and equilibrium dis-
sociation constants signiﬁcantly diminished, under condi-
tions of the full-length rPTPhs anchored in the membrane.
CONCLUSIONS
Dimerization is a well-established regulatory mechanism for
activation of RPTKs and is likely to be involved in regulation
of RPTPs. Although many protein tyrosine phosphatases
have two intracellular domains, only the plasma membrane-
proximal domain (D1) has signiﬁcant catalytic activity. Di-
meric crystallographic structure of RPTPa-D1 revealed the
presence of an NH2-terminal helix-turn-helix segment inter-
acting with the opposing monomer, in such a manner that
both catalytic sites in the dimer are blocked (24). On the
other hand, it has been shown that dimerization of Sap-1/
PTPRH, a single intracellular domain RPTP, does not occur
through its catalytic domain (59). Given a fact that rPTPh
also has a unique catalytic domain, we studied its behavior in
solution using synchrotron small-angle x-ray scattering, ho-
mology modeling, sequence alignment, and ﬂuorescence
anisotropy. Here, we provide the ﬁrst ab initio low-resolution
structure of rPTPhCD in solution restored at 1.85-nm res-
olution from synchrotron small-angle x-ray scattering data.
The results from SAXS reveal that rPTPhCD forms dimers
in solution. The ﬂuorescence anisotropy demonstrates that
the dimeric form of rPTPhCD is the predominant species in
solution with amonomer-dimer equilibrium dissociation con-
stant of 21.66 2.0 mM and a corresponding DG0293K equal to
6.2 kcal/mol. Ab initio SAXS model building, homology
modeling, and sequence analysis data of the putative rPTP-
hCD dimeric interfaces taken together strongly indicate that
rPTPh dimeric architecture might be closely related to that of
RPTPa-D1. It is tempting to speculate that dimerization of
rPTPhCD could be involved in the self-inhibition of its en-
zymatic activity. In this case the autoinhibitory mechanism
would occur through the N-terminal wedge region-active site
interactions as proposed for RPTPa-D1, a hypothesis ame-
nable to further site-directed mutagenesis analysis, and in
vivo and in vitro functional studies.
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FIGURE 6 Equilibrium ﬂuorescence anisotropy. (A) Fluorescence spectra
of buffer and ﬂuorescein-labeled rPTPhCD. (B) Measurements of rPTPhCD
dimer-monomer reaction were performed as described in experimental
procedures. The results of three independent experiments are shown as raw
anisotropy. (Inset) Fraction of association calculated from anisotropy values
properly corrected for changes in ﬂuorescence intensity. Solid line cor-
responds to the best ﬁt of Eq. 3 to data, which yields a dissociation constant
of 21.6 6 2.0 mM (r2 ¼ 0.988).
FIGURE 5 Crystallographic structures of RPTPa-D1 and RPTPm-D1.
The dimerization interfaces of RPTPa-D1 and RPTPm-D1 are shown as
surfaces. (A) The residues of RPTPa-D1 that are conserved in rPTPhCD are
shown in black; the nonconserved residues are painted in gray. (B) The same
molecule as in panel A rotated by 180 across the vertical axis. (C) The
residues of RPTPm-D1 that are conserved in rPTPhCD are depicted in
black; the ones that are nonconserved are given in gray. (D) The same
molecule as in panel C rotated by 180 across the vertical axis. The ﬁgure
was prepared using PyMOL (DeLano Scientiﬁc).
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